Antifungal treatments of candidemia in non-neutropenic patients: evaluation of practice in intensive care units

Médecine et maladies infectieuses
P MassanetJ Reynes

Abstract

The authors had for objective to assess systemic antifungal treatment for candidemia in non-neutropenic patients, in intensive care units (ICU), and compare the results with French 2004 recommendations. A retrospective multicenter study (nine ICU in two teaching hospitals) was made. Thirty-eight non-neutropenic patients with at least one positive blood culture for Candida who had received systemic antifungal treatment were included between May 2004 and September 2007. Thirty-nine cases of candidemia were analyzed. The median age was 54.5 (21-80), the median SAPS II score at admission was 44 (20-79), the median duration of stay in ICU was 22.5 days (2-82), and the death rate was 45%. Candida albicans was identified in 69% of the cases. Eight percent of Candida sp. isolates were resistant or susceptible dose-dependent (S-DD) to fluconazole. Before identification, fluconazole, caspofungin, voriconazole, and amphotericin B were used in 74%, 15%, 5%, and 5% of cases respectively. After identification and antifungal susceptibility determination, fluconazole was used in 68% of cases, caspofungin in 24% of cases, any formulation of amphotericin B in 6% of cases, voriconazole in 3% of cases. The French recommendations were applied in 71...Continue Reading

References

Sep 7, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M B EdmondR P Wenzel
Sep 19, 2003·Intensive Care Medicine·Pierre Emmanuel CharlesBernard Blettery
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olafur GudlaugssonDaniel Diekema
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Sep 3, 2004·Drugs·Helen W BoucherThomas J Walsh
Jul 16, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Juliette MorganSteven M Teutsch
Sep 2, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C LeónUNKNOWN EPCAN Study Group
Feb 5, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasUNKNOWN Infectious Diseases Society of America
May 16, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L HornKaren M Webster

❮ Previous
Next ❯

Citations

Apr 2, 2014·Annales Françaises D'anesthèsie Et De Rèanimation·P MassanetP Corne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.